Gold prices tick higher on fresh U.S. tariff threats, Fed rate cut hopes
DUBLIN - Investment firm Citadel Group has disclosed a 1.23% interest in Mural Oncology plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 214,544 shares in the oncology company as of August 4, 2025. This includes 197,491 shares owned or controlled, representing 1.13% of the company, along with derivatives positions.
The filing indicates Citadel also maintains a short position of 0.55% in Mural Oncology, consisting primarily of stock-settled derivatives including options.
The disclosure details numerous transactions conducted by Citadel, including purchases at prices ranging from $1.63 to $2.20 per share and sales between $1.62 and $2.26 per share.
The regulatory filing also lists Citadel’s options positions, including put and call options with various strike prices and expiration dates extending to January 2027.
Companies and investors are required to disclose positions of 1% or more in Irish companies that may be involved in takeover situations, though the filing does not specify whether Mural Oncology is currently the subject of an acquisition offer.
The disclosure was made through a Form 8.3 filing with the Irish Takeover Panel, which requires transparency around significant shareholdings in companies potentially involved in takeover situations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.